Home › Funds › Tri Locum Partners LP › MDGL

Tri Locum Partners LP position in MDGL

MADRIGAL PHARMACEUTICALS INC · Health Care

Tri Locum Partners LP reported holding 68,273 shares of MDGL (MADRIGAL PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$36.7M, representing 4.51% of its reported portfolio and ranking #10 among its reported holdings. Tri Locum Partners LP has disclosed MDGL holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)68.27K sh
Reported value held$36.66M
Portfolio Weight4.51%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Tri Locum Partners LP's MDGL position evolved

Tri Locum Partners LP first disclosed a stake in MDGL in Q3 2023 at 33,761 shares (US$4.9M). The position peaked in Q1 2026 at 103,288 shares, worth US$54.1M. Across 12 filings, Tri Locum Partners LP increased the stake 6 time(s), trimmed it 5 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 68,273 shares valued at US$36.7M — a reduction of -35,015 shares quarter over quarter.. Notable position changes include a 109% increase in Q1 2024 (shares rose 5% over the following quarter), a 158% increase in Q2 2025 (shares rose 52% over the following quarter), a 34% trim in Q2 2026 (shares fell 6% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 33.76K $4.93M New
Q4 2023 25.52K $5.91M Reduce
Q1 2024 53.35K $14.25M Add
Q2 2024 65.35K $18.31M Add
Q3 2024 43.29K $9.19M Reduce
Q4 2024 47.47K $14.65M Add
Q1 2025 37.87K $12.54M Reduce
Q2 2025 97.77K $29.59M Add
Q3 2025 67.71K $31.05M Reduce
Q4 2025 86.02K $50.09M Add
Q1 2026 103.29K $54.07M Add
Q2 2026 68.27K $36.66M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About MDGL and 13F data

MDGL (MADRIGAL PHARMACEUTICALS INC) is a Health Care company. 48 other funds we track also report a position in MDGL — the largest reported positions include BAKER BROS. ADVISORS LP (US$1.15B), RTW INVESTMENTS, LP (US$1.07B), Janus Henderson Group (US$1.05B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding MDGL

All MDGL fund holders →

FAQ

How long has Tri Locum Partners LP held MDGL?

Tri Locum Partners LP has disclosed MDGL holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Tri Locum Partners LP's current position in MDGL?

As of Q2 2026, Tri Locum Partners LP holds 68.27K shares of MDGL (MADRIGAL PHARMACEUTICALS INC), valued at $36.66M, representing 4.51% of its reported portfolio and ranking #10.

Has Tri Locum Partners LP been buying or selling MDGL?

In the latest 13F filing (Q2 2026), Tri Locum Partners LP reduced its position in MDGL. The position peaked in Q1 2026 at 103.29K shares.

Which other funds hold MDGL?

Other major institutional holders of MDGL include BAKER BROS. ADVISORS LP, RTW INVESTMENTS, LP, Janus Henderson Group, among 48 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.